Phase 1/2: BioNTech share significantly firmer: Pfizer and BioNTech take another step forward with COVID-19 vaccine | message

—“After our unique and robust clinical study program started in Europe and now in the United States, we look forward to moving it forward quickly with our partners at BioNTech and in consultation with the regulatory authorities,” said Albert Bourla, Pfizer Chairman and CEO . The aim is to “bring a safe and effective vaccine to the people who need it most urgently as soon as possible.”

The short amount of time, less than four months, in which people managed to move from preclinical clinical trials to humans is exceptional, added Bourla. The clinical trial is part of the global development program. Treatment of the first cohort of the clinical trial in Germany was completed last week.

In anticipation of a successful clinical development program, Pfizer are working on expanding the production capacities for global care.

BioNTech papers are currently gaining 5.29 percent on the Nasdaq to $ 48.20.

FRANKFURT (Dow Jones)